(Date:11/24/2009)...Nov. 24 NeurogesX, Inc. ...sed on developing and commercializing novel pain m...DiTonno, President and Chief Executive Officer, is...fray Health Care Conference, to be held December 1... New York. ,, Mr. DiTonno and Stephen Ghiglier...
(Date:11/24/2009)...swire/ -- Blue Marble Energy Corp. announced today...t Authority (OPDA) were recently awarded $2 millio...ization Board (CERB) in a private/public partnersh...mical biorefinery in Lincoln County, WA. ,, "...opment of our biorefinery and bring over 70 green ...
(Date:11/24/2009)...endpoint has been met for patients with advanced-s...UEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEter...Company"), a global biopharmaceutical company focu...nced positive efficacy data from a Phase 2 study w...-108 (formerly AN-152), in patients with advanced ...
(Date:11/24/2009)...4 Shire plc (LSE: SHP,N...tical company, today,announced that it has submitt...glucerase alfa, the company,s enzyme replacement t...Gaucher disease. This is the third marketing,appli...ted, with previous,submissions in the United State...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4... 11 Nektar Therapeutics,(Nasdaq: NKTR ) will an...r and,year ended December 31, 2008 on Wednesday, F...nancial markets. Howard Robin, president and chie...o review the results beginning at,5:00 p.m. Easter... press release and a live audio-only Webcast of th...
...b. 11 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB...man and Mr. Boaz Shweiger have been appointed to X...tion, Mr. Grossman will also be assuming,the role ...n, to assist in,XTL,s analysis of its strategic al...Officer of XTL, commented, "We decided to,make the...
...entists engaged in biological research and drug di...9 lab budgets. BioInformatics, LLC ( www.gene2dru...rving the life science market, has released prelim...pering in a Down Market: Strategies for Life Scien... understand current sources of funding for researc...
Other Biology Technology:Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3Life Science Labs Reacting to the Economic Crisis 2Mouse GM-CSF ELISpot Development Kit from R&D Systems
...t contains the basic components required for the d...nd recombinant rat Thymus Chemokine-1 in cell cult...ient materials to run ELISAs on approximately fift...nditions are met: The assay is run as summarized...
Custom Conjugation Services from SoluLink
Rabbit Anti-Blimp-1 (H-150) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: